No, organic eggs are not more nutritious or necessarily healthier than regular eggs. They are just far more expensive. MarthaStewart.com | September 29, 2026

https://geneticliteracyproject.org/2026/09/29/no-organic-eggs-are-not-more-nutritious-or-necessarily-healthier-than-regular-eggs-they-are-just-far-more-expensive/ Organic eggs cost considerably more than conventional ones, but that premium mostly pays for how the hens are raised, not for a more nutritious egg, as Martha Stewart’s Randi Gollin reports. When it comes to nutrition, what the hen eats matters far more than the word on the carton. The organic label means hens eat organic feed, made without grains grown with synthetic pesticides or fertilizers and without GMO grains. They’re also raised under USDA welfare rules, tightened starting in 2023 through the Organic Livestock and Poultry Standards, which require outdoor access, ban cages and prohibit forced molting. Bigger space requirements and pricier organic grain explain the higher price tag.

Viewpoint: 7-OH controversy: An opioid is available over-the-counter–even at gas stations. Should we be concerned? The Hill | September 29, 2026

https://geneticliteracyproject.org/2026/09/29/viewpoint-7-oh-controversy-an-opioid-is-available-over-the-counter-even-at-gas-stations-should-we-be-concerned/ A potent opioid is sitting on gas station shelves next to the beef jerky, and anyone with $20 can buy it, notes Liberty Vittert in an opinion piece for The Hill. To prove the point, Vittert bought a package of 7-OH, short for 7-hydroxymitragynine, in about 90 seconds. “The clerk rang it up between a coca cola and some beef jerky for my dog. He never even looked up,” she writes.

Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more Roche stopped work on an obesity drug candidate after trial data fell short

https://www.statnews.com/pharmalot/2026/09/29/novo-licenses-obesity-pill-from-china-merck-pulls-antibiotic/ By Ed SilvermanSept. 29, 2026 Pharmalot Columnist, Senior Writer

Child health is the national security crisis we keep ignoring Chronic illness, anxiety, depression, and other health problems threaten our future safety

https://www.statnews.com/2026/09/29/childrens-health-national-security-military-labor-workforce-policy-fixes/ By Tina L. Cheng, James M. Perrin, and Stanley McChrystalSept. 29, 2026 Cheng is the B.K. Rachford professor and chair of pediatrics, University of Cincinnati, and director of the Cincinnati Children’s Research Foundation. Perrin is professor of pediatrics emeritus, Harvard Medical School, and the John C. Robinson distinguished chair in pediatrics, Mass General Brigham for Children. McChrystal is a former commander of U.S. and coalition forces in Afghanistan and founder of the McChrystal Group.

She’s spent two decades talking to parents who don’t vaccinate their children. Here’s what she’s learned A sociologist on why some families skip immunizations, and why ‘misinformation’ isn’t really to blame

She’s spent two decades talking to parents who don’t vaccinate their children. Here’s what she’s learned A sociologist on why some families skip immunizations, and why ‘misinformation’ isn’t really to blame By Nicholas FlorkoSept. 29, 2026 Trust-in-Science Reporter https://www.statnews.com/2026/09/29/understanding-vaccine-skepticism-in-parents/

UniQure’s gene therapy continues to slow Huntington’s progression after four years But the magnitude of the treatment’s benefit waned compared to a similar analysis from a year ago

UniQure’s gene therapy continues to slow Huntington’s progression after four years But the magnitude of the treatment’s benefit waned compared to a similar analysis from a year ago https://www.statnews.com/2026/09/29/uniqure-huntingtons-gene-therapy-slows-disease-progression-four-years/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9u8GCVduAdt-avf7m3Kw1QbeXiCMqIrbuy2DSY82drp-okseb1VwLj82pHtTRXZd8R4Ihh7blfLBz8WQZZXWXAinQadA&_hsmi=441553206&utm_content=441553206&utm_source=hs_email By Adam FeuersteinSept. 29, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. UniQure's Huntington's benefit is less pronounced four years in UniQure’s experimental Huntington’s gene therapy AMT-130 continued to slow disease progression four years after treatment. But the magnitude of the benefit declined from a year earlier — which could potentially complicate the therapy’s regulatory review, STAT’S Adam Feuerstein writes. Among 12 patients given a high dose, AMT-130 slowed progression by 44% compared with an external natural history control group, a difference that was not statistically significant. At three years, however, the company had reported a slowing of 75%, which was statistically significant. This decrease in efficacy can partly be attributed to faster-progressing patients in the historical control group dropping out of the study, UniQure CEO Matthew Kapusta said. Still, other measures were more encouraging: AMT-130 maintained a 61% slowing in loss of functional capacity, while levels of NfL, a marker of neuronal damage, stayed close to the baseline.

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Raffaella Casolino, MD PhDa Send email to raffaella.casolino@glasgow.ac.uk ∙ Joaquin Mateo, MD PhDc ∙ Prof Elisabeth G E de Vries, MDd ∙ Amber Johns, BMedSci PhDa ∙ Melanie Courtot, PhDe,f,g ∙ Prof Rita T Lawlor, PhDj ∙ et al.

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Raffaella Casolino, MD PhDa Send email to raffaella.casolino@glasgow.ac.uk ∙ Joaquin Mateo, MD PhDc ∙ Prof Elisabeth G E de Vries, MDd ∙ Amber Johns, BMedSci PhDa ∙ Melanie Courtot, PhDe,f,g ∙ Prof Rita T Lawlor, PhDj ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5/abstract?dgcid=raven_jbs_etoc_feature_lanonc